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Abstract A capillary electrophoresis-mass spectrometry
(CE-MS) method was developed for the characterization and
integrity assessment of the Mycobacterium tuberculosis
(MTB) antigens TB10.4 and Ag85B and their chemically pro-
duced glycoconjugates, which are glycovaccine candidates
against tuberculosis (TB). In order to prevent protein adsorp-
tion to the inner capillary wall and to achieve efficient sepa-
ration of the antigen proteoforms, a polyionic multilayer coat-
ing of polybrene-dextran sulfate-polybrene (PB-DS-PB) was
used in combination with 1.5 M acetic acid as background
electrolyte (BGE). Coupling of CE to high-resolution time-
of-flight MS was achieved by a coaxial interface employing
a sheath liquid of isopropanol-water (50:50, v/v) containing
0.1 % formic acid. The MTB antigens were exposed to exper-
imental conditions used for chemical glycosylation (but no
activated saccharide was added) in order to investigate their
stability during glycovaccine production. CE-MS analysis re-
vealed the presence of several closely related degradation
products, including truncated, oxidized and conformational
variants, which were assigned by accurate mass. Analysis of
synthesized mannose conjugates of TB10.4 and Ag85B
allowed the determination of the glycoform composition
of the neo-glycoproteins next to the characterization of
degradation products which were shown to be partly
glycoconjugated. Moreover, the selectivity of CE-MS
allowed specific detection of deamidated species (protein
mass change of 1.0 Da only), indicating that chemical
glycosylation increased susceptibility to deamidation.
Overall, the results show that CE-MS represents a useful
analytical tool for the detailed characterization and opti-
mization of neo-glycoconjugate products.
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Introduction
Prevention of infectious diseases by vaccination is consid-
ered one of the most successful health treatments.
Glycoconjugate vaccines, in which oligosaccharides are
conjugated to carrier proteins (neo-glycoproteins), are
among the safest and most efficacious vaccines available
[1–3]. Since the introduction of the first glycoconjugate
vaccine against Haemophilus influenzae type b (Hib) in
1987, this strategy has been successfully applied against
numerous bacterial-infectious diseases [4].
Tuberculosis (TB) still remains one of the world’s deadliest
human diseases, ranked second only after immune deficiency
syndrome (AIDS) in the number of people killed every year.
In 2014, about 9.0 million people developed TB and 1.5 mil-
lion died [5, 6]. Even though TB is curable, the efficacy of
available chemotherapies is limited due to emerging
multidrug-resistant (MDR) and extensively drug-resistant
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(XDR) strains of Mycobacterium tuberculosis (MTB) [5].
Therapeutic vaccination against MTB has potential for the
treatment of MDR- and XDR-TB [5]. At present, Bacillus
Calmette-Guérin (BCG), the only TB vaccine in use, has ma-
jor limitations: BCG protects only infants and [7] its efficacy
wanes significantly over a period of 10–15 years [8]. Thus, the
design of an effective vaccine against TB remains an interna-
tional research priority [6]. In this context, conjugation of
antigenic proteins from MTB with arabino-mannan polysac-
charides was considered for the development of highly immu-
nogenic glycoconjugate vaccines [9].
Glycoconjugate vaccines are produced by chemical
binding of oligosaccharides to carrier proteins forming
neo-glycoproteins [10]. For this purpose, glycans are ac-
tivated targeting nucleophilic groups of amino acid resi-
dues (lysines, aspartic/glutamic acids or cysteines) of an-
tigen proteins [11]. One of the most diffused and consol-
idated methods implies the use of 2-iminomethoxyethyl
thioglycosides (IME) that selectively react with ε-amino
groups of lysine residues [12]. These glycosylation strat-
egies, however, commonly lead to a mixture of neo-gly-
coproteins with different saccharide loading numbers
and/or saccharide positionings, which may have different
properties such as clearance kinetics and/or antigenicity
[11]. Moreover, isolated or recombinantly produced car-
rier proteins, such as antigenic proteins, may not be en-
tirely pure and contain degradation products. In addition,
these proteins may undergo unwanted chemical modifi-
cations during the glycovaccine production process.
Characterization of heterogeneous neo-glycoprotein prod-
ucts evidently is a fundamental, but challenging, task
requiring not only determination of the generated
glycoforms but also characterization of potential degradation
products formed during the conjugation process in order to
ensure the production of pure and stable products during the
glycovaccine synthesis.
Mass spectrometry (MS)-based approaches are widely used
for the structural characterization of novel glycoconjugates
[13, 14]. Bottom-up approaches in which proteins are first
digested into fragments, i.e. (glyco)peptides, are mainly used
for the localization of glycosylation sites of novel (neo-)-
glycoproteins [15, 16]. We have shown the usefulness of
bottom-up liquid chromatography (LC)-MS to characterize
the glycosylation reactivity of surface amino acids of antigens
using different linkers (e.g. IME or homobifunctional (4-nitro-
phenyl ester)). This allowed selection of the optimal activation
and conjugation conditions preserving the protein antigenic
epitope after glycosylation [17]. Still, quality control of the
intact neo-glycoprotein is an important issue in biopharmaceu-
tical analysis as it provides essential information on (glycoform)
composition and protein integrity which cannot be revealed by
bottom-up approaches only. Moreover, intact analysis is rela-
tively fast, requires minimum sample treatment and avoids
unwanted modifications induced by enzymatic treatments [18,
19]. We have applied direct-infusion MS methods for the char-
acterization of the glycoform composition of intact novel
glycovaccines [17]. However, direct MS characterization of in-
tact neo-glycoproteins can be quite challenging due to their
complex (micro)heterogeneity. In addition to the inevitable
heterogeneity related to the carbohydrate component (num-
ber, structure and position), one also has to consider the
potential antigen heterogeneity caused by the presence of
e.g. proteoforms and degradation products. In particular,
distinguishing closely related variants, such deamidated
forms or conformers, might not be possible with stand-
alone MS. Therefore, separation of intact neo-glycoprotein
variants prior to MS detection is needed in order to reduce
the complexity of mass spectra and will facilitate the char-
acterization of all present species, including minor com-
ponents. Conventional reversed-phase liquid chromatog-
raphy (RPLC) of intact glycoproteins may be troublesome
due to adverse interactions with the hydrophobic station-
ary phase, leading to poor performance. Moreover, RPLC
often lacks the selectivity and efficiency to assess subtle
protein modifications and proteoforms. Recently, hydro-
philic interaction liquid chromatography (HILIC) has shown
promising possibilities for resolving intact glycoforms includ-
ing neo-glycoproteins [20–22], but coupling of protein HILIC
with MS still has to be demonstrated. Capillary electrophoresis
(CE)-MS has proved to be a useful and powerful analytical tool
for the characterization of intact proteins, glycoproteins and
drug-protein conjugates, combining high protein separation
efficiency with mass-selective detection [23–26]. Unwanted
interactions between proteins and negatively charged silanol
groups on the inner wall of fused-silica capillaries can be
prevented by applying MS-compatible coatings, allowing effi-
cient separation of proteins in a wide range of conditions [26].
CE has shown particularly useful in revealing charge hetero-
geneity among protein degradation products and impurities,
but also has shown the ability to separate positional isomers
and conformers [25, 27, 28].
In this work, we studied the potential of CE-MS for the
characterization of the antigenic MTB proteins TB10.4
(11 kDa) and Ag85B (31 kDa) which were conjugated with
2-iminomethoxyethyl-mannose (Man-IME) and 2-
minomethoxyethyl-mannose(1–6)mannose (Man(1–6)Man-
IME). These neo-glycoconjugates are candidate vaccines
against TB [17]. In order to investigate the stability of
the MTB antigens during glycovaccine production, the
proteins were analysed by the developed CE-MS method
before and after exposure to experimental conditions used
for chemical glycosylation, but with no activated saccha-
ride added. Next, the neo-glycoproteins were analysed by
CE-MS in order to determine glycoform composition as
well as to monitor the presence of glycosylation-related
degradation products.
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Materials and methods
Reagents and chemicals
All chemicals were of analytical grade. Ammonium hydrox-
ide (30 % solution), acetic acid, formic acid, isopropanol
(IPA), acetonitrile (ACN), polybrene (hexadimethrine bro-
mide, PB; average molecular weight (MW) 15,000), dextran
sulfate (DS, averageMW>500,000), benzamidine hydrochlo-
ride, sodium tetraborate and phosphate-buffered saline (PBS)
were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Deionized water was obtained from a Milli-Q purification
system (Millipore, Bedford, MA, USA). IME thioglycosides
(Man-IME andMan(1–6)Man-IME) were prepared according
to a previously reported procedure [29]. The TB10.4 and
Ag85B immunogenic proteins were obtained as recombi-
nant forms in Escherichia coli as reported by Piubelli et
a l . [8 ] and f ina l ly co l lec ted in 20 mM 3-(N -
morpholino)propanesulfonic acid (MOPS) and 0.4 M
NaCl, pH 7.0 at different concentrations.
Protein glycosylation
According to the protocol previously reported [17], the
glycosylation reaction was carried out in sodium
tetraborate buffer, 100 mM, pH 9.5. TB10.4 and
Ag85B were dissolved in the buffer in a concentration
of 5.5 mg/mL, and the solution was subsequently mixed
with IME-glycoside in a glycoside/protein molar ratio of
200/1. Benzamidine chloride was added to the reaction
mixture in order to reduce protein digestion by residual
enterokinase derived from the antigen protein production
process. The reaction mixture was vortexed for 1 min
and incubated for 24 h at 25 or 37 °C under continuous
stirring.
Sample preparation
Neo-glycoconjugate samples and antigenic proteins exposed
to glycosylation conditions for stability studies were purified
in order to remove reagents and/or salts. For this, the solutions
were submitted to four 20-min steps of ultrafiltration at
13,000g and 4 °C using Amicon® Ultra filters (Millipore,
Billerica, MA, USA) with a nominal molecular weight limit
(NMWL) of 3 or 10 kDa and a load capacity of 500 μL.
Proteins and neo-glycoproteins were finally collected and
stored in PBS. Prior to CE-MS analysis, the buffer of proteins
and their glycoconjugates were exchanged for water by two
20-min steps of ultrafiltration at 13,000g and 4 °C. All the
samples were diluted with water to a final concentration of
1 mg/mL.
Capillary electrophoresis
CE analyses were performed using a Beckman PA 800
plus instrument (Beckman Coulter, Brea, CA, USA).
Bare fused-silica capillaries with an internal diameter of
50 μm were obtained from Polymicro Technologies
(Phoenix, AZ, USA) and cut to a total length of 90 cm.
Hydrodynamic sample injections were performed at 1 psi
for 12 s corresponding to an injection volume of 12.5 nL
and an injected protein amount of 12.5 ng. UV detection
was performed at 214 nm.
For the optimized CE-MS method, the separation voltage
was −25 kV, the capillary temperature 15 °C and the back-
ground electrolyte (BGE) 1.5 M acetic acid. For the PB-DS-
PB-coating, the new bare fused-silica capillaries were
firstly rinsed with successively 1 M NaOH and water
(both 30 min at 20 psi). Subsequently, the capillaries were
flushed with 10 % (w/v) PB solution (60 min at 5 psi),
deionized water (30 min at 10 psi), 0.5 % (w/v) DS solu-
tion (60 min at 5 psi), deionized water (30 min at 10 psi),
10 % (w/v) PB solution (50 min at 5 psi), deionized water
(30 min at 10 psi) and BGE (10 min at 20 psi). Overnight,
the coated capillaries were filled with water and the tips
were immersed in vials with water.
Mass spectrometry
MS detection was performed using a maXis HD ultra-high-
resolution quadrupole time-of-flight (QTOF) mass spectrom-
eter (Rs, 80,000) (Bruker Daltonics, Bremen, Germany)
equipped with an electrospray ionization (ESI) source. CE-
MS couplingwas performed using a sheath liquid electrospray
interface from Agilent Technologies. The sheath liquid was a
mixture of IPA-water (50:50, v/v) containing 0.1 % of formic
acid and was delivered at a flow rate of 3 μL/min by a syringe
pump from Cole-Parmer (Vernon Hill, IL, USA). The mass
spectrometer was operated in positive-ion mode with an
electrospray voltage of 4.5 kV. The nebulizer gas (nitrogen)
pressure was 5 psi, and the dry gas flow rate and temperature
was 4 L/min nitrogen and 200 °C, respectively. Quadrupole
ion and collision cell energies were 5 and 8 eV, respectively.
The monitored mass range was 250–4000 m/z. Data were
analysed using Bruker Daltonics Data Analysis software
(Compass DataAnalysis, version 3.2). Extracted-ion electro-
pherograms (EIEs) were obtained with an extraction window
of ±0.1 m/z and using the smooth option of the software
(Gaussian at 1 point). Mass determinations of proteins were
performed using the BMaximum entropy deconvolution^ util-
ity. Mass accuracy employed for assignments was <20 ppm.
Theoretical masses were calculated from the amino acid se-
quence using the BPeptide mass calculator^ on IonSourceMS
(www.ionsource.com).
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Results and discussion
CE-MS method development
A BGE of acetic acid was selected for the CE-MS analysis of
TB10.4 and Ag85B, as this low-pH BGE has previously
shown good separation and ESI performance for intact pro-
teins [23]. TB10.4 and Ag85B have an isoelectric point (pI) of
4.44 and 4.77, respectively, and therefore will be positively
charged when using an acidic BGE. In order to minimize
adsorption of the proteins to the inner wall of the capillary, a
MS-compatible non-covalent multilayer capillary coating,
consisting of PB-DS-PB, was employed. Using 200 mM
acetic acid as BGE, a single symmetrical peak for TB10.4
and two partially resolved peaks for Ag85B were observed
in CE-UV. Increase of the acetic acid concentration to 2 M
(pH 2.2) resulted in an improved resolution of the Ag85B.
When using these conditions for the analysis of the Ag85B-
Man sample, two additional small peaks migrating before the
main peak were observed (Fig. S1 in Electronic Supplementary
Material (ESM)). The influence of voltage and temperature on
separation was investigated. Voltage variation between −25 and
−15 kV did not provide a significant change in the separation,
whereas decreasing the temperature from 25 to 15 °C allowed
improving considerably the resolution of peaks observed for the
Ag85B and Ag85B-Man samples. The addition of ACN (up to
20 % v/v) to the BGE was considered, but no improvement in
separation was obtained. Based on the CE-UVexperiments, the
finally selected CE conditions comprised a PB-DS-PB-coated
capillary in combination with 2 M acetic acid as BGE, a capil-
lary temperature of 15 °C and a separation voltage of −25 kV.
For coupling CE to MS, a coaxial sheath liquid interface was
employed. A sheath liquid consisting of IPA-water (50:50, v/v)
containing 0.1 % of formic acid was selected as it provided
good sensitivity and current stability. However, the BGE of
2 M acetic acid resulted in considerable ionization suppression
of the proteins. As a compromise between CE resolution and
MS sensitivity, a BGE of 1.5 M acetic acid (pH 2.3) was finally
selected.
Characterization and stability evaluation of TB10.4
and Ag85B
In order to investigate the stability of TB10.4 and Ag85B
during glycoconjugate synthesis, the protein antigens were
analysed by CE-MS before and after exposure for 24 h to
glycosyla t ion reac t ion condi t ions (see BProte in
glycosylation^), but with no activated saccharides added.
TB10.4 exposure was performed at 37 °C, being the optimum
glycosylation temperature [17]. For Ag85B, glycosylation
yields were 100 % at both 25 and 37 °C and, therefore, both
temperatures were employed in the exposure study.
TB10.4
CE-MS analysis of TB10.4 in water showed a single symmet-
ric peak at a migration time of approximately 20 min.
Deconvolution of the mass spectrum obtained in the apex of
the peak revealed a single protein molecular mass of
11,076.1 Da, which agrees well with the expected molecular
mass for TB10.4 (11,076.3 Da; see ESM, Fig. S2 for the
protein sequence and Fig. S3 for the deconvoluted spectrum).
CE-MS analysis of the TB10.4 sample after exposure to gly-
cosylation conditions (37 °C for 24 h) showed the presence of
several degradation products (Fig. 1) which could be assigned
(except peak 1) based on the masses derived from the
deconvoluted spectra (Table 1). Peaks 2 and 3 were identified
as composed of truncated protein forms that lost 4 to 17 amino
acids from the C-terminus side: A1-N86, A1-T87, A1-M88,
A1-A89, A1-M90, A1-M91, A1-A92, A1-E97 and A1-A99.
The shorter migration times of these compounds with respect
to TB10.4 most probably can be explained by the loss of two
(R93, K100) or one (K100) basic amino acid, causing a
decrease of the net positive charge. Peaks 5 and 6 were
assigned to truncated forms that lost amino acids from
the N-terminal side: M18-G103, N14-G103, Y13-G103
and S48-G103. In this case, the longer migration times com-
pared to native TB10.4 might be the consequence of the loss of
one (D5) or four (D5, D24, E38, E42) acidic amino acids. As
indicated previously [8], these truncated species might result
from aspecific protein digestion due to residual enterokinase
activity.
The base peak electropherogram (BPE) also shows a
component at 20.2 min (Fig. 1, peak 4), which is not well
resolved from TB10.4. The mass observed for this com-
ponent is 16 Da higher than the mass of TB10.4, suggest-
ing an oxidation product. Oxidation induces a relatively
small change in protein mass (+16 Da), but no change in
the protein charge, resulting in a small decrease in migration
time only.













Fig. 1 BPE obtained during CE-MS of TB10.4 which has been exposed
to glycosylation conditions at 37 °C for 24 h
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Ag85B
CE-MS analysis of Ag85B in water showed the presence of
four different species (Fig. 2a). The mass spectrum obtained
for the main peak at approximately 22.5 min (peak 0) re-
vealed, after deconvolution, a protein molecular mass of
31,345.7 Da, corresponding to the expected molecular weight
of Ag85B (31,345.6 Da; see ESM, Fig. S4 for the protein
sequence and Fig. S5 for the deconvoluted spectrum). The
deconvoluted mass spectrum of the first component (peak 1)
migrating after the main peak indicated the same mass as
Ag85B, but the recorded mass spectra showed a clearly
different charge state distribution (cf. Fig. 2a1, a2). The mass
spectrum of the main peak (Fig. 2a1) seems to comprise two
charge state distributions, which might be explained by partial
unfolding of the protein during ESI, leading to increased
charging and a shift of the distribution to lower m/z values.
Themass spectrum corresponding to peak 1 (Fig. 2a2) shows a
significantly lower relative abundance of the charge states at
lower m/z values, indicating less susceptibility to unfolding.
Peak 1 might be caused by a conformer of Ag85B exhibiting a
different electrophoretic mobility and ESI.
Deconvolution of the mass spectrum obtained for peak 2
revealed a molecular weight of 30,424.3 Da, which was
Table 1 Species observed in
BPEs of TB10.4 which has been
exposed to glycosylation
conditions (peaks 0–6) and
TB10.4 which has been
glycosylated with Man(1–6)Man-







0 20.6 11,076.1 TB10.4 11,076.3
1 17.9 9712.5 NA –
9510.4 NA –







3 19.2 10,505.8 A1-E97 10,505.6
10,647.9 A1-A99 10,647.8
4 20.2 11,092.1 Oxidized TB10.4 11,092.3
5 21.0 9191.3 M18-G103 9191.1
9636.5 N14-G103 9636.6
9799.5 Y13-G103 9799.7
6 21.4 6234.8 S48-G103 6234.8




8 18.7 11,871.3 Deamidated TB10.4-(ManMan)2 11,871.5
11,887.3 Deamidated oxidized TB10.4-
(ManMan)2
11,887.5
9 19.2 11,474.2 Deamidated TB10.4-ManMan 11,474.3
10 19.8 11,870.4 TB10.4-(ManMan)2 11,870.5
11,886.3 Oxidized TB10.4-(ManMan)2 11,886.5
11 20.4 11,473.3 TB10.4-ManMan 11,473.4
11,489.2 Oxidized TB10.4-ManMan 11,489.4
12 20.7 10,033.6 N14-G10-ManMan 10,033.7
10,196.7 Y13-G103-ManMan 10,196.8
13 20.9 9344.0 G20-G103-ManMan 9343.8
9588.4 M18-G103-ManMan 9588.2
14 21.1 6632.0 S48-G103-ManMan 6631.9
Species observed only in the glycosylated sample in italics
NA not assigned
Monitoring antigenic protein integrity using CE-MS 6127
assigned to the truncated form R10-G292. The mass spectrum
of low-abundant peak 3 indicates the same molecular mass as
peak 2. However, the mass spectra of peaks 2 and 3 differ in
their charge state distributions in a similar fashion as with
peaks 0 and 1, again suggesting the presence of two protein
conformers.
The Ag85B sample was exposed for 24 h to glycosyl-
ation conditions at both 25 and 37 °C. CE-MS analysis
(Fig. 2b, c) showed the appearance of two additional deg-
radation products (peaks 4 and 5), while the abundance of
peaks 2 and 3 increased with respect to non-exposed
Ag85B. Table 2 summarizes the peak assignment. The
considerable increase of peak 2 is mainly caused by the
formation of a new degradation product identified as the
truncated form S9-G292, which co-migrates with R10-
G292. Moreover, the abundance of R10-G292 relative to
Ag85B slightly increased from 8.6 % in the non-exposed
sample to 11.1 % in the sample incubated at 37 °C. The
compound migrating as peak 5 at 21.9 min differs from
Ag85B by +0.9 Da in mass only. Most probably, this
modification relates to a single deamidation of the protein.
Deamidation is a common protein degradation that results
in a small change of protein molecular mass (+0.984 Da)
and a shift of the pI due to the transformation of an amide
residue into an acidic residue. The relative abundance of
the degradation products was significantly lower at 25 °C.
Therefore, this temperature was selected for Ag85B
glycoconjugate synthesis.
Characterization of TB10.4 and Ag85B glycoconjugates
TB10.4 and Ag85B were conjugated with Man and Man(1–
6)Man activated as IME-glycosides according to the protocol
previously reported (see BMaterials and methods^ and Fig. S6
in ESM for the reaction scheme). The resulting glycoconjugates
were analysed with the optimized CE-MS method.
TB10.4 glycoconjugates
CE-MS analysis of TB10.4 conjugated with Man-IME and
Man(1–6)Man-IME showed the presence of several compo-
nents. The BPE obtained for TB10.4 conjugated with Man(1–
6)Man-IME is shown in Fig. 3a; the mass spectra of the two
main peaks are given in Figs. S7 and S8 in ESM. A number of
additional peaks were observed in comparison to the uncon-
jugated TB10.4 sample which was exposed to glycosylation
conditions, but with no activated saccharide added (cf. Fig. 1).
These peaks resulted mostly from the glycoconjugation of









































1500 1750 2000 2250 2500 2750 m/z
a2
0: Ag85B 0: Ag85B
Fig. 2 BPEs obtained during CE-MS of Ag85B (a) and Ag85Bwhich has been exposed to glycosylation conditions for 24 h at 25 °C (b) or at 37 °C (c).
Mass spectra obtained at the apex of peaks 0 (a1) and 1 (a2) of BPE of Ag85B (a)
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TB10.4. The main glycoconjugate species detected for the
two samples had masses corresponding to TB10.4-Man
and TB10.4-(Man)2, and TB10.4-Man(1–6)Man and
TB10.4-[Man(1–6)Man]2, respectively. TB10.4 comprises
one lysine residue as a potential glycosylation site, but as
demonstrated in our previous work [17], under the applied
glycosylation conditions, the amino functionality of the N-
terminus of the protein also can be conjugated, leading to
Table 2 Species observed during
CE-MS of Ag85B (peaks 0–3),
Ag85B which has been exposed
to glycosylation conditions for
24 h at 25 and 37 °C (peaks 0–5)
and Ag85B which has been
glycosylated with Man-IME
(peaks 6 and 7)
Peak Migration time (min) Experimental mass (Da) Assignment Theoretical mass (Da)
0 22.5 31,345.7 Ag85B 31,345.6
1 22.8 31,345.6 Ag85B conformer 31,345.6
2 23.2 30,425.4 R10-G292 30,425.5
30,512.4a S9-G292 30,512.6
3 23.6 30,425.4 R10-G292 conformer 30,425.5
30,512.4a S9-G292 conformer 30,512.6
4 21.5 31,142.7a A5-G285 31,143.3
5 21.9 31,346.8a Deamidated Ag85B 31,346.6










Species observed only in the glycosylated sample in italics
a Detected only in BPEs of Ag85B which has been exposed to glycosylation conditions
12
















































Fig. 3 BPE (a) and EIEs (b) of
most abundant ions of TB10.4
(blue), monoglycosylated TB10.4
(green) and diglycosylated
TB10.4 (red) obtained during CE-
MS of TB10.4 conjugated with
Man(1–6)Man. c zoom of b
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the formation of diglycosylated antigen. IME conjugation
does not induce a change in the protein charge (see Fig. S2
in ESM), resulting in a partial CE separation of the unmod-
ified protein and the somewhat larger glycoforms. For
TB10.4 conjugated with Man(1–6)Man-IME, a better
glycoconjugate resolution was reached due to the larger
increase in antigen size (+397 Da with respect to +235 Da
of Man-IME) upon conjugation (Fig. 3b).
The truncated species identified in the antigen stability
studies were also detected in the conjugated samples. The
truncated forms that lost a lysine residue (peaks 2 and 3 in
Table 1) with respect to native TB10.4 were detected both
unmodified and glycosylated (at the N-terminal residue).
The degradation products that still contained the lysine residue
were mainly observed as glycosylated forms (Table 1).
Interestingly, samples of TB10.4 conjugated with Man-IME
as well as with Man(1–6)Man-IME showed two additional
degradation products which were not observed during the sta-
bility studies (BCharacterization and stability evaluation of
TB10.4 and Ag85B^). These two compounds appeared to
have molecular weights differing 0.9–1.0 Da from the mono-
and diglycosylated TB10.4, respectively, and were detected at
shorter migration times (Fig. 3c). Based on the molecular mass
difference and migration time, we suppose the degradation
products to be deamidated forms of the glycoconjugates.
Partial C=C reduction and partial S–S cleavage could cause a
similar isotope shift, but only when the reduction/cleavage
product is not separated from the parent compound.
However, the degradation products are separated from the par-
ent compound and therefore most likely they are deamidated
products. In order to test this hypothesis, the deconvoluted
mass spectra of TB10.4-[Man(1–6)Man]2 and deamidated
TB10.4-[Man(1–6)Man]2 were in silico simulated (Fig. 4a)
and compared with the experimentally obtained deconvoluted
mass spectra (Fig. 4b). The striking correspondence between
the simulated and the experimental data, both showing a 1-Da
shift of the isotopic distribution for the deamidated form in
comparison with the non-deamidated one, strongly supports
our assumption that deamidation occurred. As can be seen in
Fig. 3, no deamidated form was detected for the unconjugated
form of TB10.4. This result is in agreement with the stability
study (BTB10.4^) where no deamidated species were observed
for TB10.4. Assuming equimolar ESI efficiencies for the
deamidated and non-deamidated glycoconjugates,
deamidation ratios were estimated (Table 3). Higher rates of
deamidation were obtained for the diglycosylated species
(7.1–7.3 %) in comparison with the monoglycosylated
ones (0.5–0.6 %). All together, these semi-quantitative
results indicate a correlation between deamidation inci-
dence and degree of glycosylation.
Characterization of Ag85B glycoconjugates
Ag85B has eight lysine residues in the amino acid sequence as
potential glycosylation sites. CE-MS analysis of Ag85B con-
jugated with Man-IME or with Man(1–6)Man-IME revealed
the presence of six glycoforms in both samples. Based on the
molecular weights indicated by the deconvoluted mass spectra
(see Figs. S9 and S10 in ESM), these Ag85B glycoconjugates
appeared to contain three to eight saccharide units for the Man
sample and two to seven for the Man(1–6)Man sample.
Summed extraction of the three most abundant ions for each
glycoform generated the EIEs reported in Fig. 5. The most
glycosylated species migrated faster. As with TB10.4, higher
resolution was obtained for the Man(1–6)Man glycoforms.
The broad and non-Gaussian shape of the observed peaks, as
appeared more evident for the Man(1–6)Man sample, is most
probably related to the overlap of different neo-glycoprotein
isomers characterized by the same saccharide loading number
but a different location in the amino acid sequence. Higher
conjugation efficiency was observed for the Man with an av-
erage of 5.9 saccharide units per protein whereas only an
average of 4.6 was obtained in the case of Man(1–6)Man.
11864 11866 11868 11870 11872 11874 11876 11878 11880 m/z
m/z11864 11866 11868 11870 11872 11874 11876 11878 11880
a
b
Fig. 4 Deconvoluted mass spectra showing isotopic pattern of TB10.4-
[Man(1–6)Man]2 (blue) and deamidated TB10.4-[Man(1–6)Man]2 (red)
obtained a in silico and b during CE-MS
Table 3 Relative abundance of deamidated species observed during
CE-MS of TB10.4 glycosylated with Man-IME and Man(1–6)Man-IME
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Regarding antigen degradation (see BAg85B^), only the
most abundant degradation product (S9-G292; peak 2 in
Fig. 2 and Table 2) was detected with low intensity as a mix-
ture of glycoconjugates (Table 2 for Ag85B conjugated with
Man-IME). EIE traces of Ag85B conjugated with Man-IME
and Man(1–6)Man-IME (Fig. 5a, b) show the presence of a
cluster of broadened peaks at lower migration times compris-
ing glycoform ions with similar m/z values (±0.5). These
peaks most probably correspond to a number of glycoforms
differing 1 Da, indicating the occurrence of deamidation.
Different peaks were observed in each trace suggesting the
occurrence of multiple deamidations in the same protein.
Due to the broadened peak shapes and low intensity, it was
not possible to estimate the percentage of deamidation of each
glycoform. Still, the EIEs in Fig. 5 indicate that glycoforms
with a higher number of conjugated saccharides show a great-
er susceptibility for deamidation, as was also observed for
TB10.4.
Conclusion
The potential of CE-MS for the characterization of intact neo-
glycoproteins prepared from two MTB antigens was demon-
strated. The use of a non-covalently coated (PB-DS-PB) cap-
illary in combination with an acidic BGE allowed efficient
separation of different antigen proteoforms and degradation
products. The coupling with high-resolution TOF-MS
permitted mass assignment for most of the variants observed.
The method was suitable for the characterization of protein
antigens allowing to establish the occurrence of modifications
at different stages of the glycovaccine production. For exam-
ple, CE-MS revealed the presence of conformers in Ag85B.
The method also permits evaluation of antigen integrity and
stability under glycosylation conditions and showed multiple
degradation products resulting from e.g. deamidation and
truncation. For neo-glycoprotein samples, the efficiency of
glycosylation, number of glycoforms and saccharide units
can be assessed, also showing conjugation of degradation
products. In addition, glycoform-specific deamidationwas ob-
served suggesting a relation between the number of saccharide
units and the rate of protein deamidation.
The developed CE-TOF-MS method was found suitable
for the assessment of the detailed composition of neo-glyco-
protein samples. As such, this method represents a valuable
tool for obtaining well-characterized products that will further
drive the optimization of the neo-glycoprotein production
process.
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Fig. 5 EIEs of most abundant
ions of Ag85B conjugated with 2
(light green), 3 (black), 4
(orange), 5 (blue), 6 (red), 7 (dark
green) and 8 (purple) glycan units
obtained during CE-MS of
Ag85B conjugated with aMan
and bMan(1–6)Man
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